According to a story from BioSpace, AstraZeneca and Merck released a joint announcement recently stating that the US Food and Drug Administration (FDA) has granted Orphan Drug designation to olaparib…
A new study has found that 80 percent of people who have an identifiable genetic risk for cancer due to a mutated BRCA1/2 gene don’t know they're at risk. The…
According to a report by the Stamford Advocate, The Salem Health Cancer Institute recently launched a genetic program to help improve cancer treatment. Salem Health Hospitals and Clinics report that…
According to a story from Oncology Times, a recent study indicates that the PARP inhibitor drug talazoparib could be an effective treatment option for patients with advanced, HER-2 negative, BRCA…
According to the Dover Post, there are a few crucial questions to ask your doctor upon being diagnosed with breast cancer. By asking these crucial questions, patients will be…
According to a story from rdmag.com, researchers from the University of Toronto have discovered a critical mechanism that helps facilitate the normal DNA repair process. This mechanism could have implications…
A study of Lynparza (olaparib) in combination with abiraterone for the treatment of metastatic castration-resistant prostate cancer has shown promising results. The full article can be read here, at Bio…
Denise Albert is a busy woman. She founded The MOMs media company. She enjoys music, concerts, and time with her boyfriend. She is also a happily divorced mom of two…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
